ArticleFrontiers in veterinary science2025
Comparative analysis of anthelmintic treatments: impact on liver biomarkers and clinical recovery in sheep with fasciolosis.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development of an LC-MS/MS-Based Analytical Method, In Vitro Characterization, and Pharmacokinetic Study of Rafoxanide Nanosuspension in Sheep.Animals : an open access journal from MDPI · 2026Article
- Fasciolosis: Analytical approaches to post-treatment liver enzyme activity changes in cattle.Helminthologia · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Liver fluke infections (fasciolosis) in sheep in Ethiopia result in significant economic losses, recently estimated at around $3,700 (185,232 ETH Birr) per year. Despite the widely use of Triclabendazole (TCBZ), Tetraclozan (TETRA), and Albendazole (ALBE) for treating fasciolosis, their effectiveness remains a significant concern. This study aimed to compare the efficacy of TCBZ, TETRA, and ALBE in treating ovine fasciolosis, with a focus on their effects on both the parasitic infection and associated biochemical parameters. Given the substantial economic burden of liver fluke in Ethiopia, identifying the most effective treatment options is essential to reducing both the health impact on livestock and the economic losses to farmers. Methods: A field trial was conducted from May to November 2023 on 45 naturally infected sheep, divided into three groups: Group I received TCBZ, Group II TETRA, and Group III ALBE, with TCBZ as the positive control. Fecal and serum samples were collected on days 0, 7, 14, and 21 post-treatment. A fecal egg count reduction test (FECRT) and biochemical analysis were performed. Results: In our study, TCBZ was the most effective anthelmintic (97.8%), followed by TETRA (96.6%), and ALBE (84%). Biochemical parameters, particularly liver enzymes (AST, ALT, ALP, GGT) and protein levels, showed significant improvement across all groups over 21 days ( Conclusion: TCBZ and TETRA were highly effective against ovine fasciolosis, with TETRA recommended if TCBZ is unavailable. Biochemical parameters are key biomarkers for liver damage and selecting effective anthelmintic drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.